Trials / Withdrawn
WithdrawnNCT03660072
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional | Non-Interventional |
Timeline
- Start date
- 2022-01-31
- Primary completion
- 2022-10-28
- Completion
- 2022-10-28
- First posted
- 2018-09-06
- Last updated
- 2022-05-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03660072. Inclusion in this directory is not an endorsement.